<1θ> DANMARK <1°> DK/EP 2448590 Τ3 (12) Oversættelse af europæisk patentskrift Patent- og Varemærkestyrelsen (51) Int.CI.: A 61 K 31/70 (2006.01) A 61 K 31/7008 (2006.01) A 61 K 31/7012 (2006.01) A61P 11/00(2006.01) (45) Oversættelsen bekendtgjort den: 2019-02-25 (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: 2018-10-31 (86) Europæisk ansøgning nr.: 10793441.6 (86) Europæisk indleveringsdag: 2010-07-02 (87) Den europæiske ansøgnings publiceringsdag: 2012-05-09 (86) International ansøgning nr.: AU2010000846 (87) Internationalt publikationsnr.: WO2011000053 (30) Prioritet: 2009-07-03 AU 2009903123 (84) Designerede stater: AL AT BE BG CH CY CZ DE DK EE ES Fl FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR (73) Patenthaver: Australian Biomedical Company Pty Ltd, 34 Munro Avenue, Mt Waverley, Victoria 3149, Australien (72) Opfinder: JIN, Betty, 34 Munro Avenue, Mount Waverley, Victoria 3149, Australien JONES, Paul, Arthur, 47 Yongala Street, Balwyn, Victoria 3103, Australien SEAH, Ee, Ling, 11 Hill Edge Court, Lysterfield South, Victoria 3156, Australien WU, Wen, Yang, 34 Munro Avenue, Mount Waverley, Victoria 3149, Australien JENKINS, Peter, James, 6 Grand View Grove, Prahran East, Victoria 3181, Australien (74) Fuldmægtig i Danmark: Patentgruppen A/S, Arosgården, Åboulevarden 31,8000 Århus C, Danmark (54) Benævnelse: MEDICINSKE KULHYDRATER TIL BEHANDLING AF LUFTVEJSLIDELSER (56) Fremdragne publikationer: EP-A1-1 609 473 EP-A1-2 060 257 EP-A2- 0 429 430 W0-A1 -2006/127977 W0-A1 -2009/020641 WO-A2-02/101071 JP-A- 11 206 050 US-A- 5 834 423 US-A1-2002 022 601 US-A1-2007 259 094 US-A1-2009 209 488 US-B1-6 274 568 DATABASE WPI Week 200137 Thomson Scientific, London, GB; AN 2001-344214 XP002694489, & CN 1 156 026 A (UNIV NO 3 ARMY MEDICAL PLA) 6 August 1997 (1997-08-06) Fortsættes ... DK/EP 2448590 T3 KEPPLER O ET AL: "UDP-GIcNAc 2-epimerase: A regulator of cell surface sialylation", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 284, no. 5418, 21 May 1999 (1999-05-21), pages 1372-1376, XP002164157, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.284.5418.1372 DATABASE WPI Week 199710 Thomson Scientific, London, GB; AN 1997-103654 XP002694542, & JP 8 337532 A (TAKEDA CHEM IND LTD) 24 December 1996 (1996-12-24) NAKANO T. ET AL.: 'Sialic Acid in Human Milk: Composition and Functions' ACTA PAEDIATRICA TAIWANICA vol. 42, no. 1,2001, pages 11 -17, XP009079911 VAN ALPHEN L. ET AL.:'Blocking-of Fimbria-Mediated Adherence of Haemophilus influenzae by Sialyl Gangliosides' INFECTION AND IMMUNITY vol. 59, no. 12, 1991, pages 4473 - 4477, XP008150719 SCHROTEN H. ET AL.: 'Binding of Cloned S-Fimbriated E. coli to Human Buccal, Epithelial Cells - Different Inhibition of Binding by Neonatal Saliva and Adult Saliva' ZENTRALBLATT FUR BAKTERIOLOGIE vol. 274, no. 4, 1991, pages 514 - 518, XP008150727 SCHROTEN H. ET AL.: 'Fab-Independent Antiadhesion Effects of Secretory Immunoglobulin Aon S-Fimbriated Escherichia coli Are Mediated by Sialyloligosaccharides' INFECTION AND IMMUNITY vol. 66, no. 8,1998, pages 3971 - 3973, XP008150720 ARCASOY S.M. ET AL.: 'MUCI and Other Sialylglycoconjugates Inhibit Adenovirus- Mediated Gene Transfer to Epithelial Cells' AMERICAN JOURNAL OFRESPIRATORY CELL & MOLECULAR BIOLOGY vol. 17, no. 4, 1997, pages 422 - 435, XP002951404 SCHULTE B.A. ET AL.: 'Histochemical Methods for Characterizing Secretory and Cell Surface Sialoglycoconjugates' JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY vol. 33, no. 5, 1985, pages 427 -438, XP008150721 RUHL S. ET AL.: 'Identification of Polymorphonucluear Leukocyte and HL-60 Cell Receptors for Adhesins of Streptococcus gordonii and Actinomyces naeslundii' INFECTION AND IMMUNITY vol. 68, no. 11,2000, pages 6346 - 6354, XP008150722 DOSANJH A. ET AL.: 'Expression of DELTAF508 Cystic Fibrosis Treansmembrane Regulator (CFTR) Decreases Membrane Sialylation' OPEN RESPIRATORY MEDICINE JOURNAL vol. 3, May 2009, pages 79 - 84, XP008150728 DK/EP 2448590 T3 DESCRIPTION FIELD OF THE INVENTION [0001] This invention is related to a novel method and a group of carbohydrates of Formula (1) and/or (2), and their compositions for treating cough and related respiratory conditions including post viral/bacterial infections, acute/chronic bronchitis, COPD, and inflammatory conditions. BACKGROUND OF THE INVENTION [0002] In humans, the respiratory tract, with an area of a football field is the largest surface connecting the body with the outside world required for sufficient exchange of air; meanwhile, it is affected by many physical, chemical, and biological substances in the air to cause disorders including asthma, chronic obstructive pulmonary disease, inflammatory conditions of the lung and respiratory tract. Also, some genetic disorders such as cystic fibrosis are affected by the respiratory tract's connection with the outside world. Viruses and bacteria may enter the body and cause infections in the respiratory tract to occur. [0003] Cough is one of the common conditions that needs to be treated. However, the currently available treatments are only limited in symptom relief leaving the body to recover by itself and in many cases the recoveries are sluggish. [0004] In Australia, the sale of cough syrup is over $20 million a year. It is estimated that the worldwide market of cough syrup exceeds $1 billion per annum. [0005] Persistent cough sometimes with period of normality lasting for months or even years is attributed to bronchial asthma, occult reflex, or post viral/bacterial infections and smoking causing the airway to become hypersensitive/hyperreactive. Accordingly there is a need for an efficient treatment that can assist the body to recover after it has been affected by many physical, chemical, and biological substances in the air that can cause disorders in the respiratory system. [0006] The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application. SUMMARY OF THE INVENTION DK/EP 2448590 T3 [0007] The present application discloses in one embodiment a method of promoting restoration of a sialylglycoconjugate on the surface of a damaged respiratory cell of a subject to treat a respiratory condition in the subject, the method including the step of administering to the subject at least one pharmaceutically acceptable compound capable of accelerating sialylglycoconjugate biosynthesis. [0008] In one disclosed embodiment, the method provides a recovery of viability of the cell such that the cell is in a better condition for normal biological function to respond to factors which may affect the respiratory surface thereby leading to respiratory conditions such as but not limited coughs, post viral or bacterial infections, acute/chronic bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis and other respiratory inflammatory conditions. [0009] In another embodiment, the disclosure relates to the use of a compound selected from the group consisting of compounds of Formula (1) and Formula (2) and their pharmaceutically acceptable salts and derivatives and combinations thereof. The use is for the treatment or prevention of a respiratory condition as herein described. [0010] In other aspects ofthe invention there are provided compositions and pharmaceutical compositions comprising at least one pharmaceutically acceptable compound capable of accelerating sialylglycoconjugate biosynthesis for use in the treatment and prevention of respiratory conditions. [0011] The embodiments ofthe invention are as specified in the claims. [0012] It is also described therein a method of screening for a compound for the treatment of a respiratory condition, said method comprising: subjecting a cell having reduced sialylglycoconjugates on a surface of the cell to a test compound; and measuring recovery of sialylglycoconjugates on the surface of the cell after exposure of the test compound to the cell. [0013] Measurement of the recovery of sialylglycoconjugates on the surface of the cell can be determined by a measurement of the viability of the cell. [0014] In yet another aspect of the disclosure there is provided a method of treating or preventing a respiratory condition in a subject, the method including the step of administering to the subject at least one compound identified by the screening method. BRIEF DESCRIPTION OF THE FIGURES DK/EP 2448590 T3 [0015] Figure 1 shows the biosynthesis pathway of sialylglycoconjugates in living cell. DETAILED DESCRIPTION OF THE INVENTION [0016] From cell biology and molecular biology point of view, the hypersensitivity/hyperreactivity of the damaged respiratory tract may be caused by their damaged cell surface which then will be susceptible to the stimulation of irritants. For instance, applicants have found that the respiratory tract cells after viral or bacterial infection often lost terminal sialic acids on their surface sialylglycoconjugates. As a consequence, the viability of the "naked" cell was reduced. This then trigged an inflammatory response leading to bronchitis and cough. Without being limited by theory, it is postulated that restoration of the sialic acids on the cell surface may repair the respiratory